Pathogenesis of hERG Mutations in Human Long QT Syndrome

人类长 QT 综合征 hERG 突变的发病机制

基本信息

  • 批准号:
    7624367
  • 负责人:
  • 金额:
    $ 33.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-12-05 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Long QT syndrome is a disease associated with delayed cardiac repolarization and prolonged QT intervals on the electrocardiogram, which can lead to ventricular arrhythmias and sudden death. The chromosome 7- linked inherited long QT syndrome (LQT2) is caused by mutations in the human ether-a-go-go-related gene (hERG). hERG encodes the pore-forming subunit of the rapidly activating delayed rectifier potassium channel in the heart. More than 200 hERG mutations have been identified in patients with LQT2. These LQT2 mutations result in decreased hERG channel function, which leads to action potential prolongation and cardiac arrhythmias. Most of the previous studies were focused on the analysis of mutant proteins and channel function. More than 30% of LQT2 mutations are nonsense, frameshift, or splice site mutations, which may affect hERG mRNA splicing and stability. However, the effect of LQT2 mutations on hERG mRNA splicing and stability are largely unexplored. In addition, most of the previous studies involved expressing disease-causing mutations in Xenopus oocytes or mammalian cell lines, but little is known about how LQT2 mutations function when expressed in cardiac myocytes. The specific aims of this application are: 1) To study abnormal splicing of hERG mRNA caused by splice site mutations, 2) To study whether LQT2 mutations that carry premature termination codons cause a decrease in the level of hERG mRNA transcripts by nonsense mediated mRNA decay, and 3) To study pre-mRNA splicing, mRNA stability, protein trafficking, subcellular distribution, and pharmacological rescue of LQT2 mutants expressed in cardiac myocytes. We will use molecular biology, biochemical, and electrophysiological approaches to study LQT2 mutations expressed in HEK 293 cells and in neonatal and adult rat cardiac myocytes. We will also analyze the splicing patterns and stability of endogenously expressed hERG mRNA isolated from lymphocytes of patients carrying LQT2 mutations. The results from these studies will increase our knowledge of how LQT2 mutations lead to hERG channel dysfunction at both the mRNA and protein levels. Elucidating these mechanisms will not only strengthen our understanding of the pathogenesis of hERG mutations in human long QT syndrome, but will also provide invaluable information directed towards the development of new therapeutic strategies for long QT syndrome.
描述(由申请方提供):长QT综合征是一种与心脏复极延迟和心电图QT间期延长相关的疾病,可导致室性心律失常和猝死。7号染色体连锁遗传性长QT综合征(LQT 2)是由人类ether-a-go-go相关基因(hERG)突变引起的。hERG编码心脏中快速激活延迟整流钾通道的成孔亚基。在LQT 2患者中已发现超过200种hERG突变。这些LQT 2突变导致hERG通道功能降低,从而导致动作电位延长和心律失常。以往的研究大多集中在突变蛋白和通道功能的分析上。超过30%的LQT 2突变是无义、移码或剪接位点突变,可能影响hERG mRNA的剪接和稳定性。然而,LQT 2突变对hERG mRNA剪接和稳定性的影响在很大程度上尚未探索。此外,大多数以前的研究涉及在非洲爪蟾卵母细胞或哺乳动物细胞系中表达致病突变,但对LQT 2突变在心肌细胞中表达时如何发挥作用知之甚少。本申请的具体目的是:1)研究剪接位点突变引起的hERG mRNA异常剪接,2)研究携带提前终止密码子的LQT 2突变是否通过无义介导的mRNA衰变引起hERG mRNA转录水平的降低,3)研究前体mRNA剪接、mRNA稳定性、蛋白运输、亚细胞分布,和心肌细胞中表达的LQT 2突变体的药理学拯救。我们将使用分子生物学、生物化学和电生理学方法来研究HEK 293细胞以及新生和成年大鼠心肌细胞中表达的LQT 2突变。我们还将分析从携带LQT 2突变的患者淋巴细胞中分离的内源性表达hERG mRNA的剪接模式和稳定性。这些研究的结果将增加我们对LQT 2突变如何在mRNA和蛋白水平上导致hERG通道功能障碍的了解。阐明这些机制不仅将加强我们对人类长QT综合征中hERG突变的发病机制的理解,而且还将为开发长QT综合征的新治疗策略提供宝贵的信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ZHENGFENG ZHOU其他文献

ZHENGFENG ZHOU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ZHENGFENG ZHOU', 18)}}的其他基金

Post-transcriptional regulation of Kv11.1 (hERG) channel expression by alternative splicing and polyadenylation
通过选择性剪接和多聚腺苷酸化对 Kv11.1 (hERG) 通道表达进行转录后调控
  • 批准号:
    10626127
  • 财政年份:
    2022
  • 资助金额:
    $ 33.65万
  • 项目类别:
Post-transcriptional regulation of Kv11.1 (hERG) channel expression by alternative splicing and polyadenylation
通过选择性剪接和多聚腺苷酸化对 Kv11.1 (hERG) 通道表达进行转录后调控
  • 批准号:
    10442308
  • 财政年份:
    2022
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    7229524
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of HERG Mutations in Human Long QT Syndrome
人类长 QT 综合征中 HERG 突变的发病机制
  • 批准号:
    6683227
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    8302318
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    7844826
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    8961627
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    8452065
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of hERG Mutations in Human Long QT Syndrome
人类长 QT 综合征 hERG 突变的发病机制
  • 批准号:
    9243297
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:
Pathogenesis of HERG Mutations in Human Long QT Syndrome
人类长 QT 综合征中 HERG 突变的发病机制
  • 批准号:
    6421525
  • 财政年份:
    2001
  • 资助金额:
    $ 33.65万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 33.65万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 33.65万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 33.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 33.65万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 33.65万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 33.65万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 33.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 33.65万
  • 项目类别:
    Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 33.65万
  • 项目类别:
    Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 33.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了